Compare Godaddy Inc (GDDY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs TG Therapeutics Inc — how do they compare? Godaddy Inc trades at $104.37 (market cap $13.07B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Godaddy Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and TG Therapeutics Inc for 16 Days on average.
| GDDY | TGTX | |
|---|---|---|
Market Cap | $13.07B | $8.16B |
Volume | 1,831,274 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $135.18 | $59.06 |
52-Week Low | $75.07 | $26.94 |
Typical Hold Time | 64 Days | 16 Days |
Enterprise Value | $15.75B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.37, up 7.37% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and revenue growth to $4.95 billion in 2025. However, a class action lawsuit filed in September 2026 alleging securities fraud during September 2025 to February 2026 has created negative sentiment, though analyst consensus remains predominantly buy-rated.
The outlook is mixed; strong profitability and consistent earnings beats support upside potential, but legal risks and a current price above the $96.20 consensus target warrant caution. Key risks include litigation outcomes and competitive pressures in web services, while institutional analyst support at 57.9% buy ratings provides a cushion against near-term volatility.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
